Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Polymer Additive Manufacturing Market Size, Share, Forecast, & Trends Analysis by Offering (Hardware, Materials, Services), Technology (FDM, SLA,...
-
Condensed Interim Financial Statement of Eik fasteignafélag hf. the period 1. January to 31. March 2025 was approved by the Board of Directors and the CEO on 8th of May 2025 The main results from the...
-
Macroeconomic indicators give reason to believe that the decline in the Estonian construction market has halted and that the market is stabilizing. The Infrastructure segment is also supported this...
-
TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb...
-
Dublin, May 05, 2025 (GLOBE NEWSWIRE) -- The "Cardiovascular Image Fusion Software Market - A Global and Regional Analysis: Focus on Application, End User, and Country-Level Analysis - Analysis and...
-
Company announcement number 37/2025 2 May 2025 Company announcement for...
-
eQ Plc interim report29 April 2025 at 8:00 AM January to March 2025 in brief During the period under review, the Group's net revenue totalled EUR 14.0 million (EUR 16.5 million from 1 Jan. to 31...
-
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients...
-
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1 Results reinforce...
-
The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic...